ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Clinical trial NCT05746559 · TERMINATED

Trial details

NCT number: NCT05746559
Sponsor: Alexion Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Kidney Disease CKD Cardiac Disease Cardiopulmonary Bypass

Start date: 2023-04-06
Primary completion: 2025-10-07
Enrollment: 555

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.